Tatva Chintan Pharma Chem Limited Q1 FY27 Earnings Call Summary

Event Participants

Executives

2 Ajesh Pillai, Chintan Shah

Analysts

8 Gourab Paul, Ketan Chheda, Nirali Gopani, Pal, Raman K.V., Rohit, Sarang Desai, Shlok Patel

Financials & KPIs

Geographic & Segment Commentary

• Phase Transfer Catalysts (PTC): Revenue of ₹42.8 crores grew 47% YoY and 38% QoQ. Growth is supported by structural shift toward PTC as a process-enabling, greener chemistry across the chemical value chain. Management noted that PTC is forward-integrated into SDA and Electrolyte Salts, so external sales may moderate as internal consumption rises, while continuing to cater to loyal long-term customers.
• Structure Directing Agents (SDA): Revenue of ₹57.8 crores grew 47% YoY and 10% QoQ. Euro 7 implementation has begun translating into revenue with visible customer demand; management expects gradual geographical rollout over 3-5 years (Europe first, then US, Japan, China, India). China demand has not yet picked up, but rest-of-world demand is strengthening, and Euro 7 removes prior geographical sales limitations.
• Electrolyte Salts & Solutions (ESS): Revenue of ₹6.3 crores was up 76% YoY but down 52% QoQ, due to severe short supply of key raw materials from the Middle East crisis. Demand for energy storage electrolytes is growing broadly in line with expectations, mainly from stationary energy storage customers; the hybrid battery customer is advancing toward commercial supply, with full-scale commercialization expected around late 2027. Products serve zinc and supercapacitor batteries, not lithium-ion.
• Pharma & Agro Intermediates and Specialty Chemicals (PASC): Revenue of ₹58.4 crores grew 25% YoY and 63% QoQ. Recently commercialized molecules are seeing repeat orders and improving demand; one pharma intermediate commenced commercial production in Q1, with two more pharma molecules expected to commercialize in the later half of FY27. Monoglyme is produced at a decent scale through existing infrastructure, but capacity expansion is withheld due to aggressive Chinese pricing.
• Semiconductor Chemicals: First commercial plant-scale batch was delivered and successfully qualified by the customer during Q1. The product is a key starting block for semiconductor manufacturing, with additional applications in PCB etching and circuit cleaning. Five semiconductor products are in the pipeline: one at plant scale, one at pilot under customer evaluation, and three in development; large-scale commercialization is not expected before Q4 2028.

Company-Specific & Strategic Commentary

• Greenfield Manufacturing Facility: The Board approved a new greenfield facility with an investment of approximately ₹200 crores; groundbreaking is scheduled for 20 July 2026. The multipurpose, multiproduct plant will support commercialization of R&D-ready products and cater to growing domestic demand, with expected peak revenue of ~₹300 crores at 1.2x-1.5x asset turnover. Operations are targeted within 21 months, with an internal push for 18 months; Dahej is nearly saturated, making this new site critical for growth beyond ₹800-850 crores revenue.
• Continuous Flow Chemistry: Two commercial products currently use continuous flow chemistry; ~7-8 products in the pipeline will incorporate electrochemistry or continuous flow. Conversion from batch to flow improves productivity, lowers cost, and compresses chemistry stages, enabling higher revenue from existing infrastructure. Management has made this a core focus.
• Semiconductor Qualification Progress: Beyond the qualified plant-scale batch, one product is at pilot scale under customer evaluation and three are in development. Management expects 3-4 plant-scale trials over the next 2 years before commercial scale-up can be discussed; the milestone validates R&D, manufacturing excellence, and quality systems.
• Customer Commitments for New Facility: Management has informal customer commitments for the greenfield capacity, though no official contracts are in place; customers have expressed willingness to buy once the company successfully cracks the required chemistries.
• China Anti-Involution: Potential removal of Chinese subsidies/VAT benefits for specialty, pharma, and agro intermediates is expected from January 2027, which could benefit Tatva Chintan. Management remains cautious as this is not yet law.

Guidance & Outlook

Risks & Constraints

Q&A Highlights

PTC Growth and Outlook

• Question: What drove the strong PTC growth, and can similar numbers continue in coming quarters? (Shlok Patel)
• Answer: Demand is rising due to widening acceptability of phase-transfer catalysts across the chemical industry. However, Tatva forward-integrates PTC into SDA and Electrolyte Salts, so as internal consumption increases, external PTC sales may moderate while the company continues to serve loyal customers. (Ajesh Pillai)

Glymes and PASC Product Outlook

• Question: Can you provide an outlook on glymes sold for lithium-ion batteries and other molecules in the segment? (Shlok Patel)
• Answer: Tatva does not sell to lithium-ion battery manufacturers; monoglyme is produced via conventional chemistry at a decent scale, with limited battery exposure and most sales going to the pharma industry. Capacity expansion was withheld because Chinese pricing became too aggressive. (Chintan Shah)

FY27 Execution Risks

• Question: What is the biggest execution risk to achieving FY27 guidance – customer demand, raw material volatility, or commercialization of new products? (Pal)
• Answer: None; management does not foresee any obstacles because demand across segments is quite visible. (Ajesh Pillai)

Pharma Molecule Revenue Guidance

• Question: What incremental revenue do the 3 new pharma molecules contribute in FY27, and how much can they scale in FY28? (Raman K.V.)
• Answer: The molecules should contribute around ₹70-80 crores in FY27, with a gradual uptick next year; at full utilization, the 3 molecules can generate around ₹200 crores. (Ajesh Pillai)

Semiconductor Qualification and Opportunity

• Question: Which product has been qualified, where is it used in the value chain, and what is the total addressable market? (Raman K.V.)
• Answer: The qualified product is a key starting block for semiconductor manufacturing, also used in PCB etching and circuit cleaning; the most stringent specification (semiconductor starting block) has been cleared. Five semiconductor products are in the pipeline: one at plant scale, one at pilot under evaluation, and three in development. 3-4 plant-scale trials are expected over the next 2 years before commercialization discussions begin; large volumes are unlikely before Q4 2028. (Chintan Shah)

Greenfield Capex and Capacity Strategy

• Question: What is the ₹200 crore greenfield capex for, what revenue can it generate, and when will it be operational? (Raman K.V.)
• Answer: The facility is multipurpose and multiproduct, designed for scaling up R&D-ready products and meeting domestic demand; expected peak revenue is ~₹300 crores at 1.2x-1.5x asset turnover. Operations are targeted within 21 months, with an internal push for 18 months; Dahej is nearly saturated, so the new site is needed for growth beyond ~₹850 crores. (Chintan Shah, Ajesh Pillai)

Electrolyte Salts Guidance and Raw Material Impact

• Question: Are you sticking to the earlier 10% revenue contribution guidance for Electrolyte Salts in FY27, and how will you scale from ₹6.3 crores in Q1? (Raman K.V.)
• Answer: Guidance is ₹40-60 crores for FY27; capacities and customer demand are in place, but Q1 lost a couple of months due to key raw material unavailability caused by the Middle East crisis. Orders are not a formal order book but happen on a quarter-on-quarter basis. (Chintan Shah)

Revenue Growth Composition – Volume vs Pricing

• Question: Is Q1 revenue growth volume-driven or pricing-driven, given pricing was an issue in recent quarters? (Nirali Gopani)
• Answer: Growth is largely volume-led; pricing contribution is marginal because Tatva had not fully passed on cost increases. Price pass-on to customers began 40-50 days ago and is gaining acceptance as global raw material prices remain elevated. (Chintan Shah)

SDA and Euro 7 Geographic Outlook

• Question: With China's diesel truck demand shifting to EVs, how does Euro 7 help, and which geographies will drive SDA growth? (Sarang Desai)
• Answer: Euro 7 is currently implemented only in Europe, with gradual rollout to US, Japan, China, and India over the next 3-5 years. Demand is driven by large diesel engines rather than passenger vehicles; China has not yet picked up, but rest-of-world demand is strengthening. Euro 7 removes prior geographical limitations, helping Tatva grow market share. (Chintan Shah)

Continuous Flow Chemistry and Long-term Growth

• Question: How many products use continuous flow, what benefits does it deliver, and what growth/ROIC can the company target? (Rohit)
• Answer: Two commercial products currently use continuous flow; ~7-8 products in the pipeline will use electrochemistry or continuous flow. Benefits include higher productivity, lower cost, and fewer chemistry stages. Management sees 20-25% CAGR over the next 3-4 years and targets 20-22% ROIC; asset turnover expectations have shifted from ~3x for earlier chemistries to 1.5x for complex multistage intermediates. There are no plans for contract manufacturing as the organic pipeline is sufficient. (Chintan Shah)

Monoglyme and Flame Retardant Status

• Question: What happened to the monoglyme capacity expansion and the flame retardant product? (Ketan Chheda)
• Answer: Installed monoglyme equipment was repurposed for producing raw material for supercapacitor electrolyte; monoglyme is still produced in a few hundred tons using conventional chemistry. Chinese price collapse ($4.6-4.8/kg to $2.1/kg in 30 days) caused the pullback; prices have recovered to $3-3.5/kg, but large-scale investment is not attractive. Flame retardants remain uneconomical and are not being commercialized in the near future. (Chintan Shah)

Key Takeaway

Tatva Chintan Pharma Chem reported operating revenue of ₹167.1 crores in Q1 FY27 (up 43% YoY, 25% QoQ) and EBITDA of ₹32.3 crores (up 86% YoY, 15% QoQ), driven largely by volume growth across PTC, SDA, and PASC. The quarter marked key strategic milestones: the first commercial plant-scale semiconductor batch was qualified by a customer, one pharma intermediate began commercial production, and the board approved a ₹200 crore greenfield facility to address Dahej's near-saturation and support growth beyond ₹800-850 crores revenue. Management maintained FY27 guidance of 25-30% revenue growth, 20-22% EBITDA margins, and ₹40-60 crores Electrolyte Salts revenue, despite Q1 margin pressure from delayed raw material cost pass-through and Middle East crisis-related supply disruptions. Watch points include Chinese pricing aggression, semiconductor qualification timelines (large-scale commercialization only after Q4 2028), and timely execution of the 18-21 month greenfield project. The company expects 20-25% CAGR over the next 3-4 years, backed by a mature pipeline of 8-9 products commercializing before 2028.